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Finally Mature Enough*Stéphane Rinfret, MD, SM,y Suzanne J. Baron, MD, MSC,z David J. Cohen, MD, MSCzS ince its introduction more than 30 years ago,the techniques of percutaneous coronary inter-vention (PCI) have advanced tremendously.
Balloon angioplasty spawned the birth of interven-
tional cardiology as a genuine subspecialty. Unfor-
tunately, this treatment was associated with both
acute vessel closure and longer-term restenosis,
prompting the need for more deﬁnitive endovascular
solutions (1). With the advent of bare-metal stents
(BMS), PCI subsequently matured, as teenagers even-
tually do. Compared with its infancy, akin to when
children rely on their parents for their security, stents
provided an important measure of security and inde-
pendence such that PCI could be weaned from the
frequent need for cardiac surgical bailout to treat
potentially acute catastrophic complications and
longer-term vessel failure (2). The once “precocious
PCI” was now on a ﬁne trajectory toward maturity
and adulthood.
Nevertheless, BMS were still hampered by neo-
intimal proliferation as the dominant mechanism for
long-term stent failure, which occurred in #30% of
patients (3,4). This became the Achilles heel of PCI. In
its teenage years, the medical device industry inves-
ted billions of dollars in search of an effective pre-
vention to in-stent restenosis. Ultimately, a solution
was developed in the form of drug-eluting stents
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combat smooth muscle cell proliferation within the
stent. The arrival of DES as an effective means of
decreasing restenosis rates marked the maturation of
PCI into early adulthood. Although initial hopes that
restenosis had been “cured” (5) were not ultimately
realized, early trials of both the sirolimus-eluting
stent (SES) and the paclitaxel-eluting stent (PES)
versus BMS demonstrated profound reductions in
both angiographic restenosis and the need for target
vessel revascularization (TVR) procedures (6,7). With
these advances, many thought PCI had overcome its
limitations and was ready to face its seemingly bright
future. The sky was blue again for PCI, at least up
until its mid-twenties, when it suddenly faced a po-
tential lethal challenge.
During the now-famous 2006 European Society of
Cardiology meeting in Barcelona, a storm cloud began
to form over the entire ﬁeld of DES and PCI. During
this congress, a seminal meta-analysis evaluating
hard outcomes with SES and PES versus BMS revealed
an increased risk of stent thrombosis (ST) not only in
the ﬁrst year after PCI but also beyond that time point
(8). The ﬁrestorm was further stoked by a simulta-
neous report of real-world 4-year results from two
registries from Switzerland and the Netherlands,
indicating that the 2 DES were associated with late ST,
steadily occurring at an annual rate of 0.4 to 0.6% (9).
Now facing the peril of the sword of Damocles,
many began to ponder as to whether DES, which were
originally engineered for reducing the risk of a rela-
tively benign clinical condition, namely restenosis,
were actually worth the risk. As a responsible young
adult, the PCI specialty and its academic and industry
partners undertook tremendous research efforts to
better understand these late thrombotic events. Many
culprits were identiﬁed: delayed endothelialization,
probably caused by polymer-induced vessel inﬂam-
mation; delayed hypersensitivity reactions, coupled
with insufﬁcient antiplatelet therapy; and perhaps
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2509interventional cardiologists themselves, who prob-
ably pushed the limit of the technology beyond
known safety borders at that time (10,11).
Ultimately, these efforts culminated in the
development of newer-generation DES, including
everolimus-eluting stents (EES) and zotarolimus-
eluting stents (ZES), which used more biocompatible
polymers and thinner strut platforms, all with the
goal of reducing late ST and restenosis. In animal
models and in US Food and Drug Administration–
driven clinical trials, these newer-generation DES
appeared superior to their ﬁrst-generation cous-
ins, and these attributes—combined with enhanced
deliverability—led to the gradual replacement of
ﬁrst-generation DES in routine clinical practice.
Despite their rapid adoption into clinical practice,
several important questions remained. Are second-
generation DES truly safer than previous stent de-
signs with respect to ST? And, most importantly,
have these improvements in stent technology led to
meaningful improvements in clinical outcomes for
our patients?SEE PAGE 2496In this issue of the Journal, Palmerini et al. (12)
provide us with the most comprehensive appraisal
to date of the long-term risks associated with the
various approved stents. With the use of the
increasingly popular technique of network meta-
analysis, they have summarized the data from a to-
tal of 51 randomized trials of alternative stent designs
involving >52,000 patients with a median follow-up
of 3.8 years. Not surprisingly, they found that rates
of TVR were lower with all DES compared with BMS;
however, cobalt-chromium (CoCr) EES, platinum
chromium (PtCr)-EES, SES, and BES had the lowest
rates of TVR (12). More importantly, however, they
found that CoCr-EES were associated with lower rates
of deﬁnite ST, myocardial infarction, and even mor-
tality compared with BMS, PES, and SES, and with
less stent thrombosis than BES.
This well-executed analysis summarizes an enor-
mous quantity of aggregated data and thus provides
substantial reassurance about the safety and efﬁcacy
on current-generation DES that are in common clin-
ical use. Perhaps the most surprising ﬁnding of this
study is the suggestion that second-generation DES
lead to reduced mortality compared with BMS and
ﬁrst-generation DES. Although several observational
studies have suggested a similar decrease in mortality
(13,14), this is the ﬁrst study to be on the basis
of randomized trial data to demonstrate reduced
mortality with second-generation DES—speciﬁcally,
CoCr-EES. Whether these beneﬁts also apply to othersecond-generation DES (such as PtCr-EES and Reso-
lute ZES) remains uncertain, because of the relative
paucity of randomized, clinical trials evaluating these
stent designs. Indeed, a pairwise comparison within
the network meta-analysis of those three stents with
respect to the risk of mortality, myocardial infarction,
or ST all include a null effect in the credible interval.
Given the outstanding outcomes demonstrated by
current DES technology, it is reasonable to question
whether bio-resorbable scaffolds—the newest itera-
tion of stent technology—can truly provide incre-
mental beneﬁts at any reasonable cost with respect
to the clinically important outcomes.
This ﬁnding of reduced long-term mortality with
newer-generation DES compared with both ﬁrst
generation DES and BMS has profound implications
for the ﬁeld of PCI. Indeed, if current-generation
DES are truly associated with improved survival,
then this ﬁnding calls into question the results of
both previous comparisons between PCI and either
medical therapy or coronary artery bypass grafting,
most of which have demonstrated no mortality
beneﬁt of PCI (generally with the use of BMS or ﬁrst-
generation DES) in patients with stable coronary ar-
tery disease (15,16). These results therefore raise the
question as to whether these historic trials need to
be repeated, now with the use of another current-
generation DES.
Before leaping to this conclusion, however, it is
important to consider potential mechanisms for the
apparent improvements. Experiments that used ani-
mal models have demonstrated that the ﬂuoro-poly-
mer–coated CoCr-EES is associated with less platelet
deposition and thrombosis compared with non-
coated BMS (17). However, it seems unlikely that
this mechanism would explain reductions in very late
ST, at which time full endothelial coverage of BMS
would be expected. Perhaps it is possible that treat-
ment of recurrent restenosis—as seen more frequently
with BMS as opposed to DES—eventually takes a toll
in the form of complications from repeated hospital-
izations and procedure, thereby leading to increased
mortality with BMS (18). Although no clinical trials of
DES have been powered to detect mortality differ-
ences, the large sample size afforded by network
meta-analysis, such as the one described herein, is
ideally suited to detecting such modest effects.
It is also possible that the reduced mortality rate
seen with CoCr-EES relates to a subtle form of
confounding that might still exist within the ran-
domized trials that form the basis for this study.
Historically, patients treated with BMS have tended
to receive short-term dual-antiplatelet therapy
(DAPT) (e.g., 1-month), whereas an extended duration
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(a minimum of 6 to 12 months). Because most of the
studies included in this meta-analysis did not dictate
when DAPT should be discontinued, variation in
DAPT duration prescribed with newer-generation DES
might explain this long-term difference, rather than
the stent itself. Indeed, the recently published results
of the DAPT and PEGASUS trials suggest that a longer
duration of DAPT is associated with lower rates of
cardiac events (19,20).
Regardless of the underlying mechanism, the re-
sults of this meta-analysis provide considerable
reassurance to the practicing clinician that current-
generation DES have largely eliminated the risk of
late, catastrophic, stent-related events. As a result,
we now have reached a major milestone in the
maturation of PCI as a treatment for obstructive cor-
onary artery disease. The once-precocious youth of
PCI appears to have fought its demons adequately
and, as such, has become both safer and more efﬁ-
cacious. If PCI ultimately follows a life-course akinto humans, one would expect it to grow old and
eventually die, particularly if advances in phar-
macology can either prevent or reverse the conse-
quences of atherosclerosis. That said, for now, it
appears that PCI is alive and well, allowing us to
safely relieve angina and even to potentially ex-
tend the lives of our patients. Although PCI has
already grown into a mature adult, only the future
will determine whether these techniques or their
offspring may allow the ﬁeld to remain “forever
young.”
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